{"id":"W2546853358","doi":"10.1182/blood.v114.22.790.790","title":"Preliminary Results of Southwest Oncology Group Study S0106: An International Intergroup Phase 3 Randomized Trial Comparing the Addition of Gemtuzumab Ozogamicin to Standard Induction Therapy Versus Standard Induction Therapy Followed by a Second Randomization to Post-Consolidation Gemtuzumab Ozogamicin Versus No Additional Therapy for Previously Untreated Acute Myeloid Leukemia.","year":2009,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":183,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia","funders":"","keywords":"Gemtuzumab ozogamicin; Medicine; Interim analysis; Cytarabine; Internal medicine; Randomization; Induction chemotherapy; Randomized controlled trial; Surgery; Oncology; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006035124,0.001605646,0.001833634,0.0003730287,0.0004452969,0.00085781,0.001001984,0.001734843,0.006788627],"category_scores_gemma":[0.003389584,0.0005247889,0.002461179,0.0004891737,0.001274247,0.0008214493,0.0004709721,0.00388769,0.00104737],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008388307,"about_ca_system_score_gemma":0.002779713,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001431093,"about_ca_topic_score_gemma":0.004666006,"domain_scores_codex":[0.99826,0.001342583,0.00007679711,0.0001156155,0.00008549976,0.0001196017],"domain_scores_gemma":[0.9970208,0.001107415,0.0005058805,0.0001991632,0.0001430333,0.001023848],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9654502,0.0101409,0.00191411,0.0003993796,0.0009767256,0.00004238691,0.0000771695,0.0005627386,0.003239222,0.0002173456,0.003602171,0.01337774],"study_design_scores_gemma":[0.8853573,0.1071821,0.003768298,0.00004235918,0.0007310507,0.00003401235,0.0000242533,0.0003415425,0.0006418489,0.000231694,0.001630433,0.00001506959],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9640042,0.004160466,0.00117837,0.003015174,0.0007040489,0.01117893,0.009056826,0.0001754163,0.006526539],"genre_scores_gemma":[0.9412854,0.004415899,0.006937925,0.005823097,0.0008502647,0.01531665,0.01743585,0.00009879007,0.00783617],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006788627,"threshold_uncertainty_score":0.03191715,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03119918099127266,"score_gpt":0.3468058883991452,"score_spread":0.3156067074078726,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}